As government funding dries up, Pfizer expects to charge private payers $110+ for Covid-19 vaccine

Amber Tong

For months, companies behind Covid-19 vaccines and therapies have been talking about transitioning to a private commercial market once the government funding dries up. As …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As government funding dries up, Pfizer expects to charge private payers $110+ for Covid-19 vaccine

Amber Tong

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

As gov­ern­ment fund­ing dries up, Pfiz­er ex­pects to charge pri­vate pay­ers $110+ for Covid-19 vac­cine

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

As government funding dries up, Pfizer expects to charge private payers $110+ for Covid-19 vaccine